CD38 and plasma cell myeloma: Similarly, HMCL xenografts have been used to evaluate AMG 701, a half-life extended BITE that binds to BCMA on myeloma cells and CD3 on T cells (79), and to demonstrate that the therapeutic efficacy of daratumumab in myeloma may be enhanced when CD38 in NK cells has been deleted (80).